Gennex Laboratories Ltd531739Corporate

Pharmaceuticals Latest results: Jun 2026 14 quarters of data

₹10.63

MCap ₹255 Cr · P/E 16.0

Gennex Laboratories Ltd — Stock analysis & AI research Gennex Laboratories Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹35 Cr

Sales · Jun 2026

+35.2% YoY

₹3 Cr

Operating Profit · Jun 2026

-12.5% YoY

8.5%

OPM % · Jun 2026

-35.6% YoY

₹4 Cr

Net Profit · Jun 2026

-4.7% YoY

—

EPS · Jun 2026

📝 Gennex Laboratories Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Gennex Laboratories Ltd reported revenue of ₹35 crore for the quarter ended June 2026 (Q1 FY27), up 35.2% from ₹26 crore in the same quarter last year, and down 5.5% sequentially over the March 2026 quarter.

Net profit fell 4.7% year-on-year to ₹4 crore, from ₹4 crore.

Operating profit stood at ₹3 crore — an operating margin (OPM) of 8.5%, compared with 13.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Gennex Laboratories Ltd posted revenue of ₹124 crore, a growth of 26.4% over FY25, with a net profit of ₹16 crore (up 14.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹133 crore with a net profit of ₹16 crore.

Valuation snapshot

At the current price of ₹10.63, 531739 has a market capitalisation of ₹255 crore and a trailing P/E of about 16.0.

Within the Pharmaceuticals industry, it is the 21st-largest of the 82 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 23.63%, public shareholders 76.36% of Gennex Laboratories Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹255 Cr

Current Price ?

₹10.6

P/E ?

16.02below ind

Industry P/E ?

22.40

P/B ?

1.17

P/S ?

1.91

P/FCF ?

-5.55

Enterprise Value ?

₹278 Cr

EV/EBITDA ?

15.22

PEG ?

0.30

Earnings Yield ?

6.2%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹133 Cr

OPM ?

13.7%

Profit after tax (TTM) ?

₹16 Cr

EPS (TTM) ?

₹0.66

ROCE ?

10.0%

ROE ?

7.3%

ROA ?

5.8%

Growth

Sales — latest qtr ?

₹35 Cr

PAT — latest qtr ?

₹4 Cr

YoY qtr sales growth ?

35.2%

YoY qtr profit growth ?

-4.7%

Sales growth (3y) ?

23%

Sales growth (5y) ?

15%

Profit growth (3y) ?

54%

Profit growth (5y) ?

31%

Financial Health

Debt ?

₹23 Cr

Debt to Equity ?

0.11

Interest Coverage ?

7.2

Current Ratio ?

N/A

Ownership

Promoter holding ?

23.63%

Change in promoter holding ?

3.81%

Pledged percentage ?

N/A

Market

Return 3 months ?

-0.1%

Return 6 months ?

13.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	18	14	14	19	21	21	27	27	23	26	31	31	37	35	+35.2%	-5.5%
Operating Profit	1	4	4	4	3	3	6	6	0	3	6	6	3	3	-12.5%	-7.0%
Other Income	2	0	0	0	2	2	0	0	3	2	0	-0	1	2	-11.6%	+99.7%
Interest	1	0	0	0	0	0	0	0	0	1	1	1	1	1	-13.8%	-19.2%
Depreciation	0	0	0	0	0	0	0	0	1	0	0	0	0	0	+19.6%	-31.7%
Profit Before Tax	2	3	4	3	5	5	5	5	2	5	5	5	3	4	-13.3%	+31.4%
Net Profit	2	3	3	3	4	4	4	4	2	4	5	4	3	4	-4.7%	+32.3%
EPS	0.09	0.15	0.15	0.15	0.17	0.18	0.18	0.19	0.07	0.18	0.19	0.18	0.12	—	—	—
OPM %	7.0%	27.7%	27.9%	19.0%	14.5%	13.7%	20.9%	20.4%	0.9%	13.2%	19.1%	20.0%	8.7%	8.5%	-35.6%	-2.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹98 Cr	₹124 Cr	₹133 Cr	+26.4%
Operating Profit	₹14 Cr	₹19 Cr	₹18 Cr	+31.3%
OPM %	14.46%	15.03%	13.69%	+3.9%
NPM %	14.26%	12.95%	11.93%	-9.2%
Other Income	₹5 Cr	₹3 Cr	₹3 Cr	-42.9%
Depreciation	₹1 Cr	₹1 Cr	₹1 Cr	+2.1%
Interest	₹1 Cr	₹2 Cr	₹2 Cr	+75.7%
EBIT	₹13 Cr	₹18 Cr	₹17 Cr	+33.4%
PBT	₹17 Cr	₹18 Cr	₹18 Cr	+6.8%
Tax	—	—	₹0 Cr	—
Net Profit	₹14 Cr	₹16 Cr	₹16 Cr	+14.8%
EPS	₹0.62	₹0.67	₹0.49	+8.1%
Material Cost	—	—	₹26 Cr	—
Employee Cost	—	—	₹2 Cr	—
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	18	23	23	24	+4.3%
Reserves	61	148	162	194	+19.8%
Borrowings	1	1	1	23	+2200.0%
Other Liabilities	16	34	32	33	+3.1%
Total Liabilities	96	205	218	274	+25.7%
Fixed Assets	15	16	20	22	+10.0%
CWIP	0	1	3	5	+66.7%
Investments	8	8	8	8	+0.0%
Other Assets	73	180	188	239	+27.1%
Total Assets	96	205	218	274	+25.7%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-14	-33	-10	-40	-300.0%
Cash from Investing Activity	-1	1	3	2	-33.3%
Cash from Financing Activity	21	79	2	35	+1650.0%
Net Cash Flow	6	47	-5	-3	+40.0%
Free Cash Flow	-17	-36	-15	-46	-206.7%
CFO/OP	-315%	-260%	-92%	-269%	-192.4%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	49	74	46	102	+121.7%
Inventory Days	133	148	133	174	+30.8%
Days Payable	58	133	58	65	+12.1%
Cash Conversion Cycle	125	90	120	210	+75.0%
Working Capital Days	234	466	395	407	+3.0%
ROCE %	11%	13%	11%	10%	-9.1%

👥 Shareholding (latest 4 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	% Chg
Promoters	19.82%	23.62%	23.62%	23.63%	+0.0%
Public	80.17%	76.38%	76.39%	76.36%	-0.0%
No. of Shareholders	91,183	90,320	86,306	84,133	-2.5%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	524636 Oxygenta Pharmaceutical	₹32.25	195	—	135	-14	-5.9%	-10.1%	3.3%	-70.8%	144.5%	65.6%

❓ Frequently asked questions

What was Gennex Laboratories Ltd's revenue in Q1 FY27?

What was Gennex Laboratories Ltd's net profit in Q1 FY27?